首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration.
【24h】

MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration.

机译:microRNA-328与(非小)细胞肺癌(NSCLC)脑转移相关,并介导NSCLC迁移。

获取原文
获取原文并翻译 | 示例
           

摘要

Brain metastasis (BM) can affect approximately 25% of nonsmall cell lung cancer (NSCLC) patients during their lifetime. Efforts to characterize patients that will develop BM have been disappointing. microRNAs (miRNAs) regulate the expression of target mRNAs. miRNAs play a role in regulating a variety of targets and, consequently, multiple pathways, which make them a powerful tool for early detection of disease, risk assessment, and prognosis. We investigated miRNAs that may serve as biomarkers to differentiate between NSCLC patients with and without BM. miRNA microarray profiling was performed on samples from clinically matched NSCLC from seven patients with BM (BM+) and six without BM (BM-). Using t-test and further qRT-PCR validation, eight miRNAs were confirmed to be significantly differentially expressed. Of these, expression of miR-328 and miR-330-3p were able to correctly classify BM+ vs. BM- patients. This classifier was used on a validation cohort (n = 15), and it correctly classified 12/15 patients. Gene expression analysis comparing A549 parental and A549 cells stably transfected to over-express miR-328 (A549-328) identified several significantly differentially expressed genes. PRKCA was one of the genes over-expressed in A549-328 cells. Additionally, A549-328 cells had significantly increased cell migration compared to A549 cells, which was significantly reduced upon PRKCA knockdown. In summary, miR-328 has a role in conferring migratory potential to NSCLC cells working in part through PRKCA and with further corroboration in additional independent cohorts, these miRNAs may be incorporated into clinical treatment decision making to stratify NSCLC patients at higher risk for developing BM.
机译:脑转移(BM)在寿命期间会影响大约25%的非球体细胞肺癌(NSCLC)患者。表征将开发BM的患者表征患者一直令人失望。 microRNA(miRNA)调节靶mRNA的表达。 MiRNA在调节各种目标方面发挥作用,因此多种途径,使其成为早期检测疾病,风险评估和预后的强大工具。我们调查了可以作为生物标志物的miRNA来区分NSCLC患者,没有BM。 MiRNA微阵列分析来自来自临床匹配的NMSCLC的样品,来自七个BM(BM +)和六个没有BM(BM-)的患者。使用T检验和进一步的QRT-PCR验证,确认八个miRNA被显着表达。其中,miR-328和miR-330-3p的表达能够正确分类BM +与BM患者。该分类器用于验证队列(n = 15),它正确分类为12/15患者。基因表达分析比较A549亲本和A549细胞稳定转染的A549细胞鉴定出几种显着差异表达的基因。 Prkca是A549-328细胞中的基因之一。另外,与A549细胞相比,A549-328细胞的细胞迁移显着增加,这在Prkca敲低时显着降低。总之,MIR-328在赋予部分通过PRKCA和另外的独立队列中的NSCLC细胞赋予NSCLC细胞的迁移潜力具有作用,这些miRNA可以纳入临床治疗决策,以分层NSCLC患者以更高的开发BM风险。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号